The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. G1 Therapeutics Inc shares valued at $178,421 were sold by Bailey John E. (Jack) Jr. on May 13 ’24. At $4.79 per share, Bailey John E. (Jack) Jr. sold 37,258 shares. The insider’s holdings dropped to 452,336 shares worth approximately $1.91 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, MURDOCK TERRY L sold 8,151 shares, netting a total of over 39,034 in proceeds. Following the sale of shares at $4.79 each, the insider now holds 95,487 shares.
Before that, Umstead John W. V had sold 8,151 shares from its account. In a trade valued at $39,034, the Chief Financial Officer traded G1 Therapeutics Inc shares for $4.79 each. Upon closing the transaction, the insider’s holdings decreased to 8,151 shares, worth approximately $0.65 million.
As published in a research note from JP Morgan on January 30, 2023, G1 Therapeutics Inc [GTHX] has been rated up from an Underweight to a Neutral and the price target has been revised to $10 from $7. Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in early January. As of November 04, 2021, JP Morgan has decreased its “Neutral” rating to a “an Underweight” for GTHX.
Analyzing GTHX Stock Performance
During the last five days, there has been a drop of approximately -9.83%. Over the course of the year, G1 Therapeutics Inc shares have jumped approximately 38.36%. Shares of the company reached a 52-week high of $6.14 on 05/09/24 and a 52-week low of $2.01 on 02/13/24. A 50-day SMA is recorded $4.26, while a 200-day SMA reached $2.82. Nevertheless, trading volume fell to 0.53 million shares from 1.0 million shares the previous day.
Support And Resistance Levels for G1 Therapeutics Inc (GTHX)
According to the 24-hour chart, there is a support level at 4.13, which, if violated, would cause prices to drop to 4.04. In the upper region, resistance lies at 4.32. The next price resistance is at 4.42. RSI (Relative Strength Index) is 45.59 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.17, which suggests the price will decrease in the coming days. Percent R is at 95.05%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
